Dr. Lark is currently chief scientific officer at a clinical stage biotechnology company focused on the discovery and development of biased GPCR ligands. Dr. Lark manages the drug discovery and pre-clinical development portfolio. Prior to joining Trevena, he was vice president of biology at Centocor R&D where he was responsible for the therapeutic discovery strategy and execution in immunology, oncology, tissue remodeling and biomarkers. He was previously director of musculoskeletal diseases at GlaxoSmithKline and senior investigator at Merck Research laboratories. He has published over 115 peer reviewed papers, reviews and book chapters and is an inventor on several patents. Dr. Lark is currently PI on two NIH grants focused on characterization and development of GPCR biased ligands. Dr. Lark received his BS in microbiology from the Pennsylvania State University and his PhD in molecular biology and microbiology from the Case Western Reserve University Medical School. He completed a postdoctoral fellowship in the department of pathology at The University of Washington.